Antibody Radionuclide Conjugates Market: How Is CD20 and CD37...

added blog Botanik

2026-06-04 11:18:24

Antibody Radionuclide Conjugates Market: How Is CD20 and CD37 Targeting Creating the Lymphoma Radioimmunotherapy Segment?

Lymphoma radioimmunotherapy — the Zevalin (ibritumomab tiuxetan, Y-90), Bexxar (tositumomab, I-131), and emerging CD20/CD37 ARCs for non-Hodgkin lymphoma representing the original and resurgent radiopharmaceutical oncology segment — creates the most commercially dynamic market segment, with the Antibody Radionuclide Conjugates Market reflecting lymphoma as the radioimmunotherapy...

0 Comments 0 Shares 18 Views 0 Reviews